JP2024525797A5 - - Google Patents

Info

Publication number
JP2024525797A5
JP2024525797A5 JP2024502035A JP2024502035A JP2024525797A5 JP 2024525797 A5 JP2024525797 A5 JP 2024525797A5 JP 2024502035 A JP2024502035 A JP 2024502035A JP 2024502035 A JP2024502035 A JP 2024502035A JP 2024525797 A5 JP2024525797 A5 JP 2024525797A5
Authority
JP
Japan
Prior art keywords
heterocycloalkyl
independently selected
heteroatoms independently
bond
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024502035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525797A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/037029 external-priority patent/WO2023287928A1/en
Publication of JP2024525797A publication Critical patent/JP2024525797A/ja
Publication of JP2024525797A5 publication Critical patent/JP2024525797A5/ja
Pending legal-status Critical Current

Links

JP2024502035A 2021-07-14 2022-07-13 減少したIMiD活性を伴ってBTKを分解するための二官能性化合物 Pending JP2024525797A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221905P 2021-07-14 2021-07-14
US63/221,905 2021-07-14
PCT/US2022/037029 WO2023287928A1 (en) 2021-07-14 2022-07-13 Bifunctional compounds for degrading btk with diminished imid activity

Publications (2)

Publication Number Publication Date
JP2024525797A JP2024525797A (ja) 2024-07-12
JP2024525797A5 true JP2024525797A5 (cg-RX-API-DMAC7.html) 2025-07-22

Family

ID=82799901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502035A Pending JP2024525797A (ja) 2021-07-14 2022-07-13 減少したIMiD活性を伴ってBTKを分解するための二官能性化合物

Country Status (9)

Country Link
US (1) US20240336595A1 (cg-RX-API-DMAC7.html)
EP (1) EP4370123A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024525797A (cg-RX-API-DMAC7.html)
KR (1) KR20240035837A (cg-RX-API-DMAC7.html)
CN (1) CN118019538A (cg-RX-API-DMAC7.html)
AU (1) AU2022310182A1 (cg-RX-API-DMAC7.html)
CA (1) CA3225367A1 (cg-RX-API-DMAC7.html)
IL (1) IL309796A (cg-RX-API-DMAC7.html)
WO (1) WO2023287928A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3867242A1 (en) 2018-10-15 2021-08-25 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
EP3924350A1 (en) 2019-02-13 2021-12-22 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
CA3160713A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
KR20240029070A (ko) * 2021-07-01 2024-03-05 항저우 힐젠 테라퓨틱스 컴퍼니 리미티드 브루톤 티로신 키나아제, 이의 돌연변이체 분해제, 조성물 및 응용
MX2024004899A (es) 2021-10-26 2024-05-24 Nurix Therapeutics Inc Compuestos de piperidinilpirazina-carboxamida para tratar y prevenir el cancer y para degradar btk.
WO2025162210A1 (zh) * 2024-02-04 2025-08-07 上海超阳药业有限公司 一种具备降解酪氨酸蛋白激酶btk活性的化合物及其制备方法和用途
TW202606657A (zh) * 2024-06-27 2026-02-16 南韓商韓美藥品股份有限公司 新型異雙功能蛋白質降解劑以及包含其的藥物組成物
CN120590386A (zh) * 2025-05-30 2025-09-05 北京科莱博医药开发有限责任公司 一种喹喔啉类蛋白降解剂及其制备方法和应用
CN120617259B (zh) * 2025-06-05 2026-04-10 南昌大学第一附属医院 Btk protac化合物nx-5948的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3867242A1 (en) 2018-10-15 2021-08-25 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
CA3160713A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway

Similar Documents

Publication Publication Date Title
JP2023504147A5 (cg-RX-API-DMAC7.html)
JP2024526984A5 (cg-RX-API-DMAC7.html)
USRE49556E1 (en) Compounds and compositions as protein kinase inhibitors
JP7158383B2 (ja) C-kit阻害剤としてのベンズイミダゾール化合物
AU2017376624B2 (en) Aminothiazole compounds as c-Kit inhibitors
AU2015331166B2 (en) Compounds and compositions for modulating EGFR mutant kinase activities
JP2018532737A5 (cg-RX-API-DMAC7.html)
JP2023507669A (ja) ピリド[3,4-d]ピリミジン誘導体およびこれを含む治療用薬学組成物
JP2021525781A (ja) 核輸送モジュレーターとしての化合物およびその使用
JP2021535207A5 (cg-RX-API-DMAC7.html)
AU2019381808A1 (en) ERK inhibitors and uses thereof
JP2019530745A5 (cg-RX-API-DMAC7.html)
CA2568608A1 (en) Six membered amino-amide derivatives as angiogenesis inhibitors
RU2018134981A (ru) Конъюгаты, содержащие ингибиторы RIPK2
JP2016514718A5 (cg-RX-API-DMAC7.html)
JP2019521109A5 (cg-RX-API-DMAC7.html)
JP2016520131A5 (cg-RX-API-DMAC7.html)
RU2012124811A (ru) СПОСОБ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И ДРУГИХ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ АКТИВНОСТЬЮ КИНАЗ Bcr-Abl, c-Kit, DDR1, DDR2, ИЛИ PDGF-R
RU2014118677A (ru) Ингибиторы киназ типа polo
RU2016101548A (ru) Соединения амидов гетероарилпиридона и азапиридона
EP4237418B1 (en) Pyrimidine compounds, compositions, and medicinal applications thereof
IL257392A (en) The troarils are converted to pyrazolil and their use as drugs
EP4136073A1 (en) Substituted pyridines for the treatment of inflammatory diseases
RU2018102087A (ru) Производное 1,4-дизамещенного имидазола
JP2023531495A5 (cg-RX-API-DMAC7.html)